{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:29:33Z","timestamp":1715300973801},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,9]]},"DOI":"10.7759\/cureus.59962","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T12:18:45Z","timestamp":1715257125000},"source":"Crossref","is-referenced-by-count":0,"title":["Dual Malignancies Discovered: A Rare Case of Malignant Peritoneal Epithelioid Mesothelioma and Lung Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Mark A","family":"Potesta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Guld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Laman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.25259\/CMAS_02_08_2021","article-title":"Mesothelioma","volume":"19","author":"Rao N","year":"2022","unstructured":"Rao N, Wei S. Mesothelioma. CytoJournal. 2022, 19:10. 10.25259\/CMAS_02_08_2021","journal-title":"CytoJournal"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.21037\/asj-22-37","article-title":"An update in malignant peritoneal mesothelioma diagnosis and treatment\u2014a narrative review","volume":"3","author":"Newland JJ","year":"2023","unstructured":"Newland JJ, Molin MD, Terhune JH. An update in malignant peritoneal mesothelioma diagnosis and treatment\u2014a narrative review. AME Surgical Journal. 2023, 3:","journal-title":"AME Surgical Journal"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.11.29","article-title":"Application of immunohistochemistry in diagnosis and management of malignant mesothelioma","volume":"9","author":"Chapel DB","year":"2020","unstructured":"Chapel DB, Schulte JJ, Husain AN, Krausz T. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res. 2020, 9:3-27. 10.21037\/tlcr.2019.11.29","journal-title":"Transl Lung Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20171086","article-title":"Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer","volume":"37","author":"Luo HT","year":"2017","unstructured":"Luo HT, Liang CX, Luo RC, Gu WG. Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer. Biosci Rep. 2017, 37:10.1042\/BSR20171086","journal-title":"Biosci Rep"},{"key":"ref5","article-title":"Peritoneal mesothelioma: a review","volume":"9","author":"Bridda A","year":"2007","unstructured":"Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed. 2007, 9:32.","journal-title":"MedGenMed"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.47626\/1679-4435-2022-733","article-title":"Occupational characterization of workers exposed to asbestos: an integrative review","volume":"20","author":"Vicari K","year":"2022","unstructured":"Vicari K, Ribeiro IM, Aguiar BF, Brey C, Boller S, Miranda FM. Occupational characterization of workers exposed to asbestos: an integrative review. Rev Bras Med Trab. 2022, 20:650-8. 10.47626\/1679-4435-2022-733","journal-title":"Rev Bras Med Trab"},{"key":"ref7","article-title":"Lung cancer in non-smokers","volume":"117","author":"Dubin S","year":"2020","unstructured":"Dubin S, Griffin D. Lung cancer in non-smokers. Mo Med. 2020, 117:375-9.","journal-title":"Mo Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas P","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, et al.. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021, 397:375-86. 10.1016\/S0140-6736(20)32714-8","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/236404-dual-malignancies-discovered-a-rare-case-of-malignant-peritoneal-epithelioid-mesothelioma-and-lung-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T12:18:50Z","timestamp":1715257130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/236404-dual-malignancies-discovered-a-rare-case-of-malignant-peritoneal-epithelioid-mesothelioma-and-lung-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.59962","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}